- Home
- TLRY vs VERA Comparison
TLRY vs VERA Comparison
Compare TLRY & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- VERA
- Stock Information
- Founded
- TLRY N/A
- VERA 2016
- Country
- TLRY Canada
- VERA United States
- Employees
- TLRY N/A
- VERA N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- VERA Health Care
- Exchange
- TLRY Nasdaq
- VERA Nasdaq
- Market Cap
- TLRY 1.7B
- VERA 1.7B
- IPO Year
- TLRY 2018
- VERA 2021
- Fundamental
- Price
- TLRY $1.34
- VERA $28.46
- Analyst Decision
- TLRY Buy
- VERA Buy
- Analyst Count
- TLRY 3
- VERA 9
- Target Price
- TLRY $1.50
- VERA $62.25
- AVG Volume (30 Days)
- TLRY 90.4M
- VERA 1.1M
- Earning Date
- TLRY 10-09-2025
- VERA 11-07-2025
- Dividend Yield
- TLRY N/A
- VERA N/A
- EPS Growth
- TLRY N/A
- VERA N/A
- EPS
- TLRY N/A
- VERA N/A
- Revenue
- TLRY $830,766,000.00
- VERA N/A
- Revenue This Year
- TLRY $7.28
- VERA N/A
- Revenue Next Year
- TLRY $4.56
- VERA N/A
- P/E Ratio
- TLRY N/A
- VERA N/A
- Revenue Growth
- TLRY 2.31
- VERA N/A
- 52 Week Low
- TLRY $0.35
- VERA $18.53
- 52 Week High
- TLRY $2.32
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- TLRY 43.82
- VERA 47.03
- Support Level
- TLRY $1.28
- VERA $28.92
- Resistance Level
- TLRY $1.54
- VERA $30.41
- Average True Range (ATR)
- TLRY 0.10
- VERA 1.44
- MACD
- TLRY -0.05
- VERA -0.40
- Stochastic Oscillator
- TLRY 10.71
- VERA 20.56
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.